Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients Conference call begins at 4:30 p.m. Eastern time today BOSTON / Nov 07, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering... Read More

Public Meeting Scheduled for November 29, 2023 BOSTON / Nov 06, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (CMS) posted a proposed Medicare Durable Medical Equipment,... Read More

Standard Medicare Part B Patients now have access to the MyoPro, which will be reimbursed on a lump sum basis BOSTON / Nov 02, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (CMS)... Read More

BOSTON / Oct 31, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2023 on November 7, 2023. The Company will host a conference call the same... Read More

BOSTON / Aug 29, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "reasonable best efforts" public offering of 7,333,334 shares of common stock (or common stock equivalents in lieu thereof)... Read More

BOSTON / Aug 25, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "reasonable best efforts" public offering of 7,333,334 shares of common stock (or common stock equivalents in lieu thereof) at a public offering... Read More

BOSTON / Aug 24, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) in a “reasonable best efforts” public offering. All of the... Read More

Appropriate payment amounts received on two MyoPro claims; Additional claims are under review while CMS rulemaking to re-classify the MyoPro to the brace benefit category progresses BOSTON / Aug 24, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis,... Read More

MyoPro patients win cases against German Statutory Insurance System payers including BARMER, Germany’s second-largest statutory health insurer BOSTON / Aug 21, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that two insurers in... Read More

Q2 revenue of $6.0 million, including license revenue Nearly 1,000 prospective MyoPro® candidates with known payers in the patient pipeline Begins to build Medicare Part B patient pipeline following publication of proposed rule by the Centers for Medicare and Medicaid Services Conference call begins at 4:30 p.m. Eastern time today BOSTON / Aug 09, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the... Read More

BOSTON / Aug 02, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2023 on August 9, 2023. The Company will host a conference call the same day,... Read More

BOSTON / Jun 14, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will be participating in the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Tuesday June 20, 2023. Paul Gudonis, Myomo’s chairman and chief... Read More

BOSTON / May 03, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2023 on May 10, 2023. The Company will host a conference call the same day, Wednesday, May... Read More

Payment of $1.7 million permits the start of activities to manufacture and sell the MyoPro® in China BOSTON / Apr 10, 2023 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces receipt of the final portion of the initial license fee under the... Read More

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2022 filed on March 13, 2023 with the Securities and Exchange Commission, the audited financial statements... Read More

Fourth quarter revenue was $4.0 million, up 2% sequentially 387 patients added to the pipeline in fourth quarter, up 75% compared with Q4 2021 Conference call begins at 10:00 a.m. Eastern time today Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2022 on March 13, 2023 before the opening of the market. The Company will host a conference call the same day, Monday,... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will presenting at the 35 th Annual Roth Conference , March 13-14, 2023 at The Ritz-Carlton, Dana Point, Calif. David Henry, Myomo’s chief financial officer will participate in a “Fireside Chat”... Read More

First reimbursement leads to greater access for patients Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that for the first time, the National Disability Insurance Scheme (NDIS) in Australia approved a MyoPro for a patient with a paralyzed arm. The NDIS aids... Read More

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr.... Read More

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for... Read More

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross... Read More

Undertakes a reduction in force to enhance efficiency in its direct billing channel Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced a reduction in force for the purpose of improving operating efficiency in its direct billing channel and reduce its cash... Read More

Company to begin submitting claims after meeting with DME MAC medical directors in 2023 Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported progress and next steps in the process to obtain Medicare Part B reimbursement for the MyoPro ® as a brace from the... Read More

Prospective MyoPro patient wins case against DAK, Germany’s third-largest health insurer Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that in an appeal before the Berlin-Brandenburg Regional Social Court (L 9 KR 210/21), the court confirmed that the... Read More

Third quarter revenue of $4.0 million, up 8% sequentially 130 authorizations and orders results in a record-high backlog of 184 units Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2022 on November 10, 2022, after the market close. The Company will host a conference call the same day, Thursday,... Read More

Myomo, Inc. (NYSE American:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo's chairman and chief executive officer, will present at the Microcap Rodeo presents The Windy City Roundup 2022 conference, which is being held live, in-person on October 12th -... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at the H.C. Wainwright 24 th Annual Global Investment Conference. The Conference is being held September 12 – 14, both virtually and in New York City. Paul Gudonis, chief... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced receipt of a $120,000 order for MyoPro ® units from Cleveland’s Louis Stokes Veterans Administration (“VA”) Medical Center. The units will be used in an investigator-initiated, randomized clinical trial... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2022. Financial and operational highlights for the second quarter of 2022 include the following: Product revenue was $3.7 million, up 18% from... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2022 on August 3, 2022, after the market close. The Company will host a conference call the same day, Wednesday, August 3,... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter. Revenue for the second quarter of 2022 is expected to be $3.4 million to $3.6 million, an increase of 10% to... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo’s chairman and chief executive officer, and David Henry, Myomo’s chief financial officer, will present and provide a business update at the Sidoti Summer Small Cap Conference,... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months ended March 31, 2022. Financial and operational highlights for the first quarter of 2022 include the following (all comparisons are with the first quarter of 2021,... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2022 on May 11, 2022 after the market close. The Company will host a conference call the same day, Wednesday, May 11, 2022 at 4:30... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, provides an update on the status of its joint venture (“JV”) in China and the associated impact on first quarter 2022 revenue. As of March 31, 2022, a portion of the technology license fee from the JV Company, Jiangxi... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will participate in two investor conferences during March: 34 th Annual ROTH Conference, March 13-15, 2022 at The Ritz-Carlton, Laguna Niguel, CA. Management will participate in a “Fireside Chat”... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2021. Financial and operational highlights for the fourth quarter of 2021 include the following (all comparisons are with the fourth... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and fiscal year ended December 31, 2021 on March 9, 2022 after the market close. The Company will host a conference call the same day, Wednesday,... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the granting of patent number 6998478 titled “Powered Orthotic Device and Method of Using Same” by the Japanese Patent Office. This new Japanese patent is part of a family of patents Myomo has been issued for... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that new research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “statistically significant improvements” in a number of motor function measurements. The research study, titled... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo’s chairman and chief executive officer, and David Henry, Myomo’s chief financial officer, will present at the Sidoti Winter Small Cap Conference, which is being held virtually from... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today provided an update on reimbursement for its MyoPro device by a large private payer that was denying pre-authorized claims after delivery of devices to patients. For the three and nine months ended September 30,... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the availability of MyoPro 2+, an enhanced version of its popular MyoPro powered brace. Deliveries to patients will begin this month. Building on the MyoPro 2, MyoPro 2+ offers lighter weight, easier... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces the entry into an amended and restated joint venture agreement (the “Amended JV Agreement”) with Beijing Ryzur Medical Investment Co., Ltd. (“Ryzur Medical”) and Wuxi Chinaleaf Rehabilitation Industry Equity... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2021. Financial and operational highlights for the third quarter of 2021 include the following (all comparisons are with the third... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2021 on November 10, 2021 after the market close. The Company will host a conference call the same day, Wednesday,... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced it has entered into agreements with certain of its holders of its existing 2020 investor warrants exercisable for 1,015,798 shares of its common stock, in the aggregate, pursuant to which such holders... Read More

Myomo, Inc. (NYSE American:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo's chairman and chief executive officer, and David Henry, Myomo's chief financial officer, will present at the Fall Harvest - Best Ideas From the Buy-Side conference, which is being... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the granting of patents in China and Hong Kong covering the Company’s most advanced products. Patent number ZL201680032072 was issued in China and patent number 1251447B was issued in Hong Kong. The... Read More

Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo’s chairman and chief executive officer, and David Henry, Myomo’s chief financial officer, will participate in three investment conferences in September. They are: 2021 Colliers... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2021. Financial and operational highlights for the second quarter of 2021 include the following (all comparisons are with the second quarter of... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2021 on August 9, 2021 after the market close. The Company will host a conference call the same day, Monday, August 9, 2021... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Healthcare Quality Association on Accreditation (HQAA) has certified Myomo meets the accreditation requirements under the Social Security Act and federal regulations. Accreditation is a program in... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will participate in A.G.P.’s Virtual MedTech Summer Conference on Thursday, July 29, 2021. The event will consist of one-on-one virtual investor meetings. Investors participating in the... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that its stock will be added to the Russell Microcap ® Index at the opening of trading today. "We are delighted that Myomo is now included in the Russell Microcap ® Index, a broadly used performance... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul R. Gudonis, Chief Executive Officer, and David Henry, Chief Financial Officer, will present a corporate overview of the company at the Sidoti Virtual Investor Conference on Wednesday, June 23,... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that its shareholders, at its meeting on June 9, 2021, elected Milton Morris, PhD, as Director. Dr. Morris was elected to serve as a Class I director, with an initial term of three years until the 2024... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that CEO Paul R. Gudonis and CFO David Henry will present at the Summer Solstice – Best Ideas From the Buy Side Conference on June 1, 2021 at 2:30 p.m. Eastern time. The conference is sponsored by the... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months ended March 31, 2021. Financial and operational highlights for the first quarter of 2021 include the following (all comparisons are with the first quarter of 2020,... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2021 on May 5, 2021 after the market close. The Company will host a conference call the same day, Wednesday, May 5, 2021 at 4:30... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Thomas Jefferson University of Philadelphia has successfully completed the first phase of clinical trials using sensors imbedded in the brain to control a MyoPro powered brace worn by a stroke... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2020. Financial and operational highlights for the fourth quarter of 2020 include the following (all comparisons are with the fourth... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul R. Gudonis, Myomo’s CEO, and David Henry, Myomo’s CFO will participate in three virtual investment conferences during the month of March, as follows: The H.C. Wainwright Global Life Sciences... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2020 on March 10, 2021 after the market close. The Company will host a conference call the same day, Wednesday, March... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced Techniker Krankenkasse (TK), Germany's largest Statutory Health Insurance (SHI) company, now approves reimbursement of MyoPro on a case-by-case basis. TK covers over 10 Million insured lives and joins the... Read More

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at the Winter Wonderland – Best Ideas from the Buy-side Conference. The conference is being held virtually on February 16 th through February 19 th . Myomo’s presentation is... Read More